Evaluation of tumor markers: An evidence-based guide for determination of clinical utility

Oncology: An Evidence-Based Approach

Volumn , Issue , 2006, Pages 106-111

  Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892258471     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-31056-8_7     Document Type: Chapter

References (28)

1. ASCO Expert Panel. Clinical Practice Guidelines for the Use of Tumor Markers in Breast and Colorectal Cancer: Report of the American Society of Clinical Oncology Expert Panel. J Clin Oncol 1996;14:2843-2877.
2. ASCO Expert Panel. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1998;16:793-795.
3. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19(6):1865-1878.
4. Hayes DF, Bast R, Desch CE, et al. A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-1466.
5. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992;326(26):1756-1761.
6. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in nodenegative breast cancer patients. J Natl Cancer Inst 1993; 85(15):1206-1219.
7. Osborne CK. Receptors. In: Harris J, Hellman S, Henderson I, Kinne D (eds). Breast Diseases, 2nd ed. Philadelphia: Lippincott; 1991:301-325.
8. Trock B, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89: 917-931.
9. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-484.
10. Fisher B, Redmond C, Dimitrov N, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989;320: 473-478.
11. Ravdin PM. Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol 1999;26(4 suppl 12): 117-123.
12. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15(8):2894-2904.
13. Hayes DF. Tumor markers for breast cancer. Ann Oncol 1993; 4:807-819.
14. Trock BJ, Yamauchi H, Brotzman M, Stearns V, Hayes DF. c-erbB-2 as a prognostic factor in breast cancer: a metaanalysis. Proc Am Soc Clin Oncol 2000;2000:97a.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11):783-792.
16. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27(6 suppl 11):46-52; discussion 92-100.
17. Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
18. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3):719-726.
19. Coates AS, Simes RJ. Patient assessment of adjuvant treatment in operable breast cancer. New York: Wiley, 1992.
20. Lindley C, Vasa S, Sawyer T, Winer E. Quality of life and preferences for treatment following systemic adjuvant therapy for early stage breast cancer. J Clin Oncol 1998;16:1380-1387.
21. Siminoff LA, Ravdin P, Colabianchi N, Sturm CM. Doctorpatient communication patterns in breast cancer adjuvant therapy discussions. Health Expect 2000;3(1):26-36.
22. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19(4):980-991.
23. Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001; 19(4):972-979.
24. Whelan T, Levine M, Willan A, et al. Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA 2004;292(4):435-441.
25. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979-985.
26. Clark GM. Prognostic and predictive factors. In: Harris J, Lippman M, Morrow M, Osborne CK (eds). Diseases of the Breast, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:489-515.
27. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19(9):2334-2356.
28. Press M. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54(10): 2771-2777.